Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPS-2071 dose-ranging study in bacterial enteritis and Clostridioides difficile infection
jRCT2080222885Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of OPS-2071 in bacterial enteritis, Clostridioides difficile colitis (CDI), nontyphoidal salmonellosis and 2 more (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability of OPS-2071. Started Jun 2015; status: completed.
02
Drugs
OPS-2071
03
Conditions
bacterial enteritisClostridioides difficile colitis (CDI)nontyphoidal salmonellosiscampylobacteriosiscolibacillosis
Beyond the preview
Go deeper on jRCT2080222885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222885.